Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27624397 | 0.89 | TSHR (0.33) | TSHR | |
| SCHEMBL10710294 | 0.89 | IDO1 (0.37) | KDM4ELMNA | |
| SCHEMBL28152391 | 0.83 | GAA (0.42) | CA1CA2KDM4E | |
| SCHEMBL18705909 | 0.81 | RAB9A (0.36) | CA1CA2CA9 | |
| SCHEMBL1166414 | 0.79 | HPGD (0.33) | CA1CA2CA9 | |
| SCHEMBL160785 | 0.79 | — | — | |
| SCHEMBL128292 | 0.77 | — | — | |
| SCHEMBL6636322 | 0.77 | MEN1 (0.40) | CA2TSHRLMNA | |
| SCHEMBL2183492 | 0.77 | L3MBTL1 (0.47) | KDM4E | |
| SCHEMBL28827366 | 0.77 | CYP2C19 (0.37) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | claimed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | claimed |
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | claimed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | claimed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | claimed |
| CN-108912066-A | Therapeutical active compound and its application method | 安吉奥斯医药品有限公司 | 2018-11-30 | — | — | CN | claimed |
| CN-108698992-A | 2- cyano isoindoline derivatives for treating cancer | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | claimed |
| CN-105593215-A | 2, 4-or 4, 6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS INC | 2016-05-18 | — | — | CN | claimed |
| CN-105517996-A | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS INC | 2016-04-20 | — | — | CN | claimed |
| CN-105492435-A | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS INC | 2016-04-13 | — | — | CN | claimed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | claimed |
| US-9024038-B2 | Compunds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2015-05-05 | — | — | US | claimed |
| CN-104114543-A | Therapeutically active compounds and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2014-10-22 | — | — | CN | claimed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | claimed |
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-1922181-A | Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives | SCHERING PLOUGH ANIMAL HEALTH (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-4139537-A | 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds | COOPER LABORATORIES, INC. (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | ENPP2 1544/4885CA1 4640/4885CA2 4287/4885 |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | ENPP2 1188/4885CA1 2022/4885CA2 3225/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | ENPP2 1544/4885CA1 4640/4885CA2 4287/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | ENPP2 1188/4885CA1 2022/4885CA2 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.